

Evaluation and management of the Neurogenic bladder

Jalesh N. Panicker

Jalesh N. Panicker MD, DM, FRCP

Consultant Neurologist and Reader in Uro-Neurology and Clinical Neurology

Department of Uro-Neurology, The National Hospital for Neurology and Neurosurgery

and UCL Queen Square Institute of Neurology, London, WC1N 3BG, United Kingdom

Corresponding author

Jalesh N. Panicker, Department of Uro-Neurology, The National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology, Queen Square, London, United Kingdom.

Email: j.panicker@ucl.ac.uk

Phone: 0044(0)2034484713

Abstract

Lower urinary tract (LUT) dysfunction is a common sequel of neurological disease resulting in symptoms that have a significant impact on quality of life. The site of the neurological lesion, as well as its nature, influence the pattern of dysfunction. The risk for developing upper urinary tract damage and renal failure is considerably lower in patients with slowly progressive non-traumatic neurological disorders, as compared to those with spinal cord injury or spina bifida. This acknowledged difference in morbidity is taken into account to develop appropriate management algorithms.

The preliminary evaluation consists of history taking and a bladder diary and may be supplemented by tests such as uroflowmetry, post void residual measurement, renal ultrasound, (video-)urodynamics, neurophysiology, and urethro-cystoscopy, depending upon the clinical indications. Incomplete bladder emptying is most often managed by intermittent catheterization, and storage dysfunction by antimuscarinic medications. Intradetrusor injections of onabotulinumtoxinA have revolutionised the management of neurogenic detrusor overactivity. Neuromodulation offers promise for managing both storage and voiding dysfunction. In select patients, reconstructive urological surgery may become necessary. An individualized, patient-tailored approach is required for the management of LUT dysfunction in this special population.

Key words

Neurological disease, incontinence, botulinum toxin, tibial nerve stimulation

Introduction

The term “neurogenic bladder” is loosely used to denote lower urinary tract (LUT) dysfunction that occurs consequent to neurological disease. Lower urinary tract (LUT) is commonly reported by patients with neurological disease, and the impact on quality of life is increasingly being recognised by the practicing neurologist. Its heterogeneous presentation reflects the complexity of the neural control of the LUT, and the site of lesion in the neurological axis determines the pattern of symptoms and dysfunction. Pelvic organ dysfunction encompasses LUT, sexual and bowel dysfunction and their complex interrelationship is now much better understood, with the recognition that a holistic approach is required for management. This review presents an overview of neurological control of LUT functions in health, a clinical approach to evaluating LUT dysfunction in the context of neurological disease, and an overview of current treatment strategies.

Neurological control of LUT functions in health

A complex neural network acts as a switching circuit to maintain a reciprocal relationship between the reservoir function of the bladder and sphincter function of the urethra. This results in low-pressure filling and periodic voluntary emptying. The frequency of micturition in a person with a bladder capacity of 400 to 600 mL is once every 3 to 4 hours, and the bladder is in a storage phase for more than 99% of the time^{1 2}. Switching from the storage to the voiding phase is initiated by a conscious decision, which is influenced by the perceived state of bladder fullness and an assessment of the social appropriateness of voiding. This phasic pattern of activity, as well as degree of voluntary control and dependence on learned behaviour, is unique

to the LUT compared to other autonomically innervated structures such as the cardiovascular system¹.

Connections between the pons and the sacral spinal cord, and the peripheral innervation that originates from the caudal spinal cord need to be intact to effect storage and voiding. During bladder filling, sympathetic and pudendal nerves mediate contraction of the smooth (internal) and striated (external) urethral sphincter whereas sympathetic mediated inhibition of the detrusor prevents contractions. This results in low pressure filling and continence¹. When deemed appropriate to void, the pontine micturition centre (PMC) is released from the tonic inhibition of higher cortical centres, and parasympathetic mediated detrusor contraction accompanied by relaxation of the pelvic floor and external and internal urethral sphincters results in effective bladder emptying^{3 4}.

Neurogenic LUT dysfunction

A uro-neurological classification of neurological disorders is useful to understand that different patterns of LUT dysfunction can arise following neurological disease (Figure 1)⁵. *Detrusor overactivity* (DO) is the most common cause for urinary incontinence following neurological disease. Patients report varying degrees of storage symptoms such as urinary urgency, frequency, nocturia and incontinence (collectively known as “overactive bladder symptoms”). Damage to central inhibitory pathways or sensitization of peripheral afferent terminals in the bladder can unmask primitive voiding reflexes and be expressed as spontaneous involuntary contractions of the detrusor⁶. The mechanisms for detrusor overactivity following suprapontine damage are however different from those following spinal cord injury

(SCI). A lesion affecting the suprapontine neural network results in removal of the tonic inhibition of the PMC and involuntary detrusor contractions. Detrusor overactivity occurring following a lesion of the suprasacral spinal cord is mediated through the emergence of a spinal reflex pathway that triggers bladder overactivity. Afferent nerves conveying sensations from the LUT to the spinal cord contain unmyelinated C-fibres that have a much greater threshold for activation and are therefore quiescent in health. Following spinal cord injury (SCI), the C-fibres become sensitised and are mechanosensitive at lower bladder volumes¹. It has been shown in experimental animal models of spinal cord injury that a C-fibre afferent mediated segmental spinal reflex emerges resulting in involuntary detrusor contractions at low bladder volumes (Figure 2)^{7 8}. Additionally, normally coordinated activity between the detrusor and urethral sphincters during voiding becomes impaired, and the detrusor and urethral sphincters contract simultaneously, termed *detrusor sphincter dyssynergia* (DSD). Injury to the conus medullaris, sacral roots (cauda equina) and peripheral nerves results primarily in voiding dysfunction from poorly sustained detrusor contractions, termed *detrusor underactivity*. Patients with DSD or detrusor underactivity report different voiding symptoms that include urinary hesitancy and an interrupted urinary stream, sensation of incomplete bladder emptying and double voiding. Variations from the expected patterns of LUT dysfunction presented in Figure 1 should warrant a search for additional urological pathologies, or even neurological sites of localisation.

Parkinson's Disease and Multiple System Atrophy

The prevalence of LUT symptoms in Parkinson's Disease ranges between 38-71%, depending upon the extent and duration of disease. LUT symptoms are the commonest non-motor symptoms reported in PD⁹, and are associated with an

increased risk for falls ¹⁰, early institutionalization and escalating health-related costs.¹¹ Nocturia is the commonest LUT symptom and can arise due to impaired bladder storage from DO and from nocturnal polyuria. ^{12 13}

In multiple system atrophy (MSA), LUT symptoms occur early in the course often preceding other neurological manifestations and even orthostatic hypotension ¹⁴. Incontinence arises from detrusor overactivity and external sphincter weakness, however as the disease progresses, incomplete bladder emptying becomes the predominant feature. ¹⁵ The finding of an open bladder neck in video-urodynamic studies in men who have not undergone surgery to the bladder outlet is a suggestive sign of sympathetic denervation of the bladder neck seen in MSA. ¹⁶

Dementia

Incontinence is often a prominent symptom and contributes significantly to care-giver burden. Incontinence occurs early in normal pressure hydrocephalus, dementia with Lewy bodies, vascular dementia and frontotemporal dementia, whereas it generally occurs late in the course of Alzheimer's disease or Parkinson's disease with dementia ^{17 18}. In patients with dementia and incontinence, pharmacological treatment of one condition can exacerbate the other ¹⁹. Incontinence may result not only from detrusor overactivity, but also from cognitive and behavioural problems, urological comorbidities and immobility.

Cerebrovascular accident

More than half of stroke patients report urinary incontinence during the acute phase of stroke. Risk factors for incontinence include large lesion size, and presence of comorbid illnesses such as diabetes and older age. Lesions in the anteromedial frontal lobe, paraventricular white matter and putamen are most commonly associated with LUT symptoms. Most commonly, urodynamics shows evidence for detrusor

overactivity. Urinary retention has been reported following hemorrhagic and ischemic stroke²⁰. There is evidence to suggest that incontinence is independently associated with subsequent severity of neurological disability, institutionalization and mortality. Small-vessel disease of the white matter, leukoaraiosis, is associated with urgency incontinence, and it is now apparent that this is an important cause for incontinence in the functionally independent elderly^{21 22 23}.

Multiple sclerosis

Lower urinary tract symptoms are reported in 32-96% of patients with MS, depending upon the duration and severity of disease. Symptoms are reported on the average six years into the illness and more than 90% of patients report symptoms if the duration of disease exceeds 10 years.²⁴ Symptoms may be overlooked however and the results of a recent survey suggest that nearly half of MS patients with moderate to severe overactive bladder symptoms had not undergone an evaluation by a urologist.²⁵ Relevant to a neurology practice is that 10% of patients report LUT symptoms at the time of initial diagnosis²⁴. Most patients classify the impact symptoms have on their life as moderate or high and urinary incontinence is considered to be one of the worst aspects of the disease.²⁶ Most commonly, both storage and voiding symptoms are reported. The commonest findings in urodynamic testing are DO and DSD.²⁷

Spinal cord injury

During the stage of spinal shock, patients are often in urinary retention. They develop the typical pattern of DO and DSD over time as spinal reflexes return. Pressures within the bladder may rise considerably, increasing the risk for upper urinary tract damage. Urinary retention, bladder spasms, UTIs, interventions of the bladder and bowel, constipation and sexual activity can trigger autonomic dysreflexia in individuals with lesions at T6 spinal cord level or above²⁸.

Spina bifida

Lower urinary tract dysfunction is common in spina bifida and is reported in more than 90% of children. Dysfunction begins in utero and symptoms usually manifest soon after birth, though may be delayed till childhood, and occasionally till adulthood. Urodynamic studies demonstrate a variety of findings including detrusor overactivity, detrusor underactivity or low compliance, DSD, or a static or fixed external urethral sphincter. Young individuals may develop LUT dysfunction later on in life due to spinal cord tethering. They should therefore be regularly monitored, as they may be at risk for developing upper urinary tract complications.

Cauda equina syndrome and peripheral neuropathy

Reduced or absent detrusor contractions are commonly seen. Individuals report reduced sensation of bladder fullness, inability to initiate micturition voluntarily and bladder distension, to the point of overflow incontinence. Detrusor overactivity may however occur in a subset of patients and this may be as a result of “bladder decentralisation” due to preserved peripherally sited post-ganglionic neurons ²⁹.

Urinary retention

Urinary retention may occur following neurological disease (Table 1). ³⁰ Medications such as opiates ³¹, those with anticholinergic properties (e.g. neuroleptics, tricyclic antidepressants, respiratory agents with anticholinergic effects and antimuscarinic agents for the bladder) and alpha-adrenoceptor agonists may cause voiding dysfunction, ranging from incomplete bladder emptying to complete urinary retention. Urinary retention is relatively uncommon in young women, and if no underlying urological or neurological disease can be established, a primary disorder of urethral sphincter relaxation (called Fowler’s syndrome) should be considered. Women typically present with painless urinary retention often with volumes exceeding a litre,

in the absence of a sensation of bladder fullness. They often experience difficulty performing intermittent catheterisation, especially when attempting to remove the catheter. Urethral sphincter electromyography reveals a characteristic pattern of abnormal activity, and the urethral pressure profile is usually elevated. Sacral neuromodulation, and more recently sphincter injections of Botulinum toxin, have been shown to be effective treatments.^{32 33}

Impact of LUT dysfunction on the upper urinary tracts

In some individuals, high pressures within the LUT may affect the upper urinary tract, resulting in vesico-ureteric reflux, hydronephrosis, and in some instances renal impairment and end-stage renal disease. Patients with SCI or spina bifida are at significant risk of developing these problems, having a five or eight times risk, respectively, of developing renal failure compared to the general adult population³⁴. For reasons that are not fully understood, the prevalence of upper urinary tract damage and renal failure is much lower though in patients with slowly progressive non-traumatic neurological disorders. In Multiple sclerosis, the risk for urinary tract complications is related to length of disease and severity of disability³⁵, Parkinson's Disease and Hereditary spastic paraplegia.³⁶ The management of neurogenic LUT dysfunction should include a risk assessment of developing upper urinary tract damage: whereas those at high risk of upper urinary tract damage require life-long close urological supervision, patients with progressive neurological disease and often at low-risk, the group most often being followed up by neurologists, are much more troubled by poor LUT control than dangerously high urinary tract pressures.

Evaluation

A multidisciplinary approach involving neurologists, urologists, physiatrists and primary care is key to successful management of LUT dysfunction. An overview of the evaluation is provided in Figure 3⁵.

History taking and physical examination

Information is gathered on LUT symptoms, congenital and neurological abnormalities, prior urogenital complications and treatments, sexual and bowel complaints and impact on quality of life²⁸. Medication history should be reviewed. For example an association between opiate use and voiding dysfunction is often overlooked despite being a listed adverse effect³¹. Not infrequently, individuals may report becoming incontinent due to the inability to reach the toilet in a timely manner due to their neurological deficits or due to poor accessibility to toilets (functional incontinence).

The bladder diary provides a real-time objective patient-reported measure of LUT symptoms, which may not be obtained through history taking or questionnaires³⁷. The diary is ideally maintained for three days however to be of value, however the individual must be motivated to complete it faithfully.

Investigations

Urinalysis and urine culture (if appropriate) and blood chemistry, if not already performed by the referring physician, form part of a basic assessment.

Ultrasonography

The post void residual volume (PVR) is measured by ultrasound or “in–out” catheterization. An elevated PVR signifies that there is voiding dysfunction, however does not discern whether this is due to detrusor underactivity or bladder outflow obstruction, for which urodynamics would be required. The PVR should ideally be

measured on different occasions as the degree of bladder emptying varies at different times and in different circumstances^{38 39}.

In patients known to be at high-risk of upper urinary tract disease, ultrasonography should be performed periodically to screen for upper urinary tract dilatation or renal scarring ²⁸. Ultrasound may also be used to demonstrate urinary tract stones which may develop in patients with neurogenic LUT dysfunction.

Urodynamic investigations

Non-invasive urodynamic tests

Uroflowmetry provides a valuable non-invasive assessment of voiding functions and the PVR is usually measured with the test. The pattern and rate of flow depend on detrusor function and bladder outlet resistance.

Invasive urodynamic tests

Combined cystometry and pressure-flow study, with or without simultaneous fluoroscopic monitoring (i.e. video-urodynamics), assess detrusor and bladder outlet function and provide information about detrusor pressure and compliance. Urodynamics testing help to establish the pathophysiological basis for LUT symptoms, but also serves as a tool to assess risk for upper tract damage as discussed earlier.

The place of urodynamics in the evaluation of LUT symptoms in neurological patients is a matter of ongoing debate ³⁸. For example in the assessment of LUT functions in patients with early multiple sclerosis, urodynamics is recommended by the French guidelines ²⁴ whereas in the United Kingdom, the recommended first line management involves testing for urinary tract infections and PVR measurement without invasive urodynamics ³⁹. In the absence of studies comparing these two models, the decision

to perform complete baseline urodynamics would depend upon local recommendations and resources.

Other tests

Other LUT pathologies may co-exist with LUT symptoms and cystoscopy (combined with bladder washing cytology if appropriate) is indicated when urethral stricture, bladder stones, and bladder tumours are suspected ²⁸.

Measuring serum creatinine, and calculating the glomerular filtration rate (eGFR) yield a reasonable estimation of renal function with minimal cost and inconvenience. The GFR is most accurately measured using renal scintigraphy which is recommended when renal function is poor, in individuals with reduced muscle mass, if function for each renal unit has to be assessed separately and in high-risk patients ²⁸.

Pelvic neurophysiology

The role of pelvic electromyography (EMG) in the assessment of individuals with established neurological disease is limited. Pelvic floor EMG was first introduced as part of urodynamic studies with the aim of recognising DSD. However it is less commonly performed nowadays with the advent of video-urodynamics testing. Sphincter muscle EMG is useful in evaluating the innervation of the sacral 2nd, 3rd and 4th innervation when cauda equina syndrome is suspected ⁴⁰, or sometimes in patients presenting with a parkinsonian syndrome to aid in the differential diagnosis between idiopathic Parkinson's disease and MSA ⁴¹. Urethral sphincter EMG has proven to be useful in the evaluation of young women in urinary retention when Fowler's Syndrome is suspected ⁴².

Management

The goals of management are to achieve urinary continence, improve quality of life, prevent urinary tract infections and preserve upper urinary tract function ²⁸. The

management of neurogenic LUT dysfunction should address both voiding and storage dysfunction and is influenced by the severity of symptoms and risk for developing upper urinary tract damage. Adopting an approach that includes evaluating LUT symptoms, risk assessment for upper tract impairment and regular review after instituting treatment provides a framework for the practicing neurologist to manage LUT dysfunction in their patients with progressive non-traumatic neurological disorders. The different treatment options are presented in Figure 4⁵. There are situations where specialist urology services should be involved early in the care of these patients (Table 2).

Managing storage dysfunction

Antimuscarinic agents

Competitive antagonism of the muscarinic receptors results in detrusor relaxation and lower intravesical pressures. Since the introduction of oxybutynin, several newer antimuscarinic agents have appeared on the market (Table 3) and have been shown to be efficacious in neurogenic OAB^{43 44 45 46 47}. The findings of systematic reviews suggest that the only difference between medications is their side effect profile^{48 49}. Prescribing patterns of these agents are determined by local guidance.

The common adverse effects include dry mouth, blurred vision for near objects, constipation and occasionally tachycardia. These symptoms are often reported by individuals with neurological disease already and therefore must be reviewed before commencing the medication. The post-void residual (PVR) may increase after starting an antimuscarinic agent and therefore should be monitored in case of a poor-response to treatment, or paradoxical worsening of symptoms.³⁹

Several of the antimuscarinic agents can cross the blood brain barrier and through their effects on central muscarinic receptors can result in adverse effects such as

alterations in cognition and consciousness. Increasing the anticholinergic burden from cumulative use of medications with anticholinergic properties may be associated with worsening cognitive functions, MRI findings of brain atrophy, decline in physical functions and falls.^{50 51 52} In susceptible individuals such as the elderly, it would appear sensible to recommend the use of an antimuscarinic agent with minimal effects on the central muscarinic receptors. Trospium chloride is relatively impermeable to the blood brain barrier because of its physicochemical properties, and darifenacin has greater affinity for the M3 receptor sub-type of relevance to the LUT compared to the M1 sub-type which is prevalent in the brain.^{53 54 55} However, evidence supporting their use in clinical practice based on this consideration is limited⁵⁶.

Beta-3-receptor agonists

The beta-3 receptor agonist mirabegron has been licensed for managing overactive bladder symptoms. Although devoid of the adverse effects reported with antimuscarinic agents, side effects do occur which include palpitations, raised blood pressure and rarely atrial fibrillation.⁵⁷ Studies suggest that mirabegron is efficacious in patients with MS and SCI with tolerable side effect profiles.^{58 59}

Desmopressin

Desmopressin, a synthetic analogue of arginine vasopressin, temporarily reduces urine production and volume determined detrusor overactivity, by promoting water re-absorption at the distal and collecting tubules of the kidney. It is useful for the treatment of urinary frequency or nocturia in patients with MS, providing symptom relief for up to six hours⁶⁰. It is also helpful in managing nocturnal polyuria, characterised by increased production of urine in the night, a disorder seen in patients with Parkinson's disease and also various neurological conditions associated with orthostatic hypotension. However, it should be prescribed with caution in patients over the age of

65 or with dependent leg oedema, and should not be used more than once in 24 hours for fear of hyponatremia or congestive heart failure.

Botulinum toxin

Since the first reports of the use of Botulinum toxin injections into the detrusor in patients with SCI^{61,62}, several studies have been carried out demonstrating the treatment to be highly effective, safe, and well tolerated, culminating in two pivotal phase III studies of onabotulinumtoxinA.^{63,64} Benefits seem to occur regardless of the underlying neurological disorder, however data on conditions other than SCI and MS are scarce. 200 units of onabotulinumtoxinA is injected in the bladder wall requiring cystoscopy, an intervention that can be performed under local anaesthesia in most neurological patients. Long-term data confirm the efficacy of repeat onabotulinumtoxinA injections^{65,66}, and cost-effectiveness is superior to best supportive care.³⁸

Neuromodulation

Electrical stimulation of the sacral nerve roots, tibial nerve, pudendal nerve and dorsal genital nerves, has been shown to be effective in managing the idiopathic overactive bladder. Electrical stimulation of the tibial nerve has been shown to be a safe and effective treatment for LUT storage symptoms and for bowel dysfunction.⁶⁷ Stimulating the nerve using a fine gauge needle (Percutaneous tibial nerve stimulation, PTNS) has been shown to improve overactive bladder symptoms and urodynamic parameters in patients with MS and PD.^{68 69} A typical treatment course consists of using a fixed frequency electrical signal for 30 minutes over the course of 12 sessions. PTNS is a minimally invasive option for managing patients with mild/moderate overactive bladder symptoms and is associated with few adverse effects. Moreover, it is one of the few options for the overactive bladder not associated

with worsening voiding dysfunction and incomplete bladder emptying.⁷⁰ However, effects are relatively short lived and the need to return for maintenance top-up treatments is influenced by the degree of improvement of LUT symptoms.⁷¹ Alternatively, the nerve can be stimulated using a cutaneous electrode (Transcutaneous tibial nerve stimulation, TTNS) and therefore may be performed at home. This treatment has been shown to be safe and effective in patients with MS and stroke experiencing urgency incontinence.^{72 73}

Managing voiding dysfunction

Voiding dysfunction may not be apparent from history and measuring the PVR therefore is integral. A significantly high residual urine after voiding may exacerbate detrusor overactivity, thereby worsen storage symptoms and rendering treatments such as antimuscarinics and botulinum toxin less effective. Moreover, a high PVR volume predisposes the patient to recurrent UTIs.⁷⁴ If the PVR is found to be consistently elevated, catheterisation, preferably intermittently, is indicated and greatly improves management. The PVR volume considered to be significant at which point intermittent self-catheterisation should be initiated however lacks consensus. Many patients with neurogenic LUT dysfunction have a reduced bladder capacity, and therefore a PVR consistently more than 100 mL, is often taken as the amount of residual urine that warrants treatment if the patient is symptomatic.³⁹ A trained health care professional such as a continence advisor should assess whether neurological deficits (poor manual dexterity, weakness, tremor, rigidity, spasticity, impaired visual acuity or cognitive impairment) may be barriers to successful catheterisation.⁷⁵ The frequency of catheterization depends upon several factors such as bladder capacity, fluid intake, PVR, and also urodynamic parameters. Patients in complete urinary retention will need to catheterize four to six times per 24 hours. The incidence of

symptomatic urinary tract infections is low when performed regularly.^{39 74} In patients not suitable for intermittent catheterisation, a urethral or (preferably) suprapubic indwelling catheter would need to be considered.

Triggered reflex voiding can occasionally be achieved by provoking a bladder contraction, such as suprapubic tapping and thigh scratching, and is most successful in patients with a suprasacral spinal cord lesion. However these manoeuvres should be used with caution as they may provoke a rise in intravesical pressures²⁸. Likewise, bladder expression using Valsalva or Credé manoeuvres is usually not recommended²⁸. Suprapubic vibration using a mechanical “buzzer”⁷⁶ and the use of alpha-adrenergic blockers have been advocated by some groups³⁹. Botulinum toxin injections into the external urethral sphincter may improve bladder emptying in patients with SCI who have significant voiding dysfunction⁷⁷.

Surgical treatment

Surgical interventions should be considered in cases where these first and second line treatments have failed. Nowadays surgery is increasingly becoming uncommon for progressive nontraumatic neurological conditions due to the availability of less invasive options (figure 4)⁵.

Follow-up of patients with neurogenic LUT dysfunction

In the absence of long-term natural history studies, there is a lack of consensus about how often patients with neurogenic LUT dysfunction should be followed up. The population with high risk for upper tract damage should be followed up more regularly with a patient-tailored approach aiming to achieve an optimal quality of life and to protect the upper urinary tract. Follow up should reflect regional guidelines based upon resource allocation²⁸.

Urinary Tract Infections in neurological patients

Recurrent urinary tract infections (UTIs), defined as more than two UTIs in 6 months, or more than three in a year, commonly occur in neurological patients and are an important cause for hospital admissions. It is important to distinguish recurrent infections from persisting infections as undertreatment of the latter may result in chronic infections. A high post void residual can predispose to UTIs and the incidence of symptomatic UTIs often falls when intermittent catheterization is performed regularly.

An evaluation would include assessing for incomplete bladder emptying (e.g. bladder outflow obstruction, reduced detrusor contractility, etc.) or a structural abnormality (foreign body in bladder, bladder stone, tumour, etc.), and for this reason the input of a Urologist would be valuable. In individuals with proven recurrent urinary tract infections and when no urological structural abnormality has been identified, it would be reasonable to initiate non-antibiotic options such as cranberry extract tablets or D-mannose⁷⁸. Prophylactic low-dose antibiotics for a finite duration may be required; rotating between antibiotics is one approach for minimizing antibiotic resistance developing⁷⁴. The value of cranberry juice in preventing urinary tract infections in neurogenic patients is debatable⁷⁹.

Conclusions

LUT dysfunction is common in neurological patients and has a significant impact on quality of life. Neurologists are increasingly enquiring about LUT functions and becoming involved in the management of these complaints. However collaboration with other specialists including urologists are highly recommended in order to maximize patients' quality of life.

Acknowledgements

JNP undertook this work at UCLH/UCL Institute of Neurology and is supported in part by funding from the United Kingdom's Department of Health NIHR Biomedical Research Centres funding scheme.

List of figures

Figure 1. The pattern of LUT dysfunction following neurological disease is influenced by the site of lesion. PVR: post void residual

PERMISSION REQUIRED ⁵

Figure 2. Two types of afferent nerves convey sensations of bladder filling.(a) In health, thinly myelinated Ad fibres have a lower threshold for activation and are responsible for conveying sensations of bladder filling. Whereas, unmyelinated C-fibres have a greater threshold for activation and are thought to be quiescent. (b) Following spinal cord damage, C-fibres become sensitized and are mechanosensitive at lower bladder volumes. A segmental spinal reflex emerges that is mediated by C-fibres afferents nerves and results in involuntary detrusor contractions, the basis for NDO. LUT, lower urinary tract;NDO, neurogenic detrusor overactivity. PERMISSION REQUIRED ⁷

Figure 3. Assessment of the neurological patient reporting LUT symptoms⁵
PERMISSION REQUIRED

Figure 4. Management of LUT dysfunction in the neurological patient. In the case of combined storage and voiding dysfunction, treat the more dominant component first. Treatments appearing in italics are supported only by limited evidence⁵.
PERMISSION REQUIRED

List of Tables

Table 1. The differential diagnosis for urinary retention in a patient where a structural urological lesion has been excluded³⁰

1. Lesions of the conus medullaris or cauda equina

Compressive lesions

Spine fracture

Intervertebral disc prolapse

Space occupying lesions- tumour, granuloma, abscess

Non-compressive lesions

Vascular- infarction, AV malformation with vascular steal

Inflammation- myelitis, meningitis retention syndrome

Infection- herpes simplex, varicella zoster, cytomegalovirus, Elsberg syndrome (viral aseptic meningitis)

2. Other neurological conditions

Spina bifida

Multiple System Atrophy

Autonomic failure, eg. Pure Autonomic Failure, autonomic neuropathies

3. Miscellaneous

Medications- eg. opiates, anticholinergics, retigabine

Radical pelvic surgery

Fowler's Syndrome (females)

Table 2. Red flags warranting a referral to a specialist urology service

- Haematuria
- Recurrent urinary tract infections
- Pain suspected to be originating from the urinary tract
- Increased risk for upper urinary tract damage, or findings of upper tract damage or renal impairment in imaging or blood tests
- Suspicion of concomitant urological or gynaecological pathologies, eg. bladder outlet obstruction due to prostate enlargement in men or stress incontinence in women
- Lower urinary tract symptoms refractory to conservative treatments- consideration of more invasive treatments such as intradetrusor injections of Botulinum toxin A or surgery, or when suprapubic catheterization appears appropriate

Table 3. List of commonly used antimuscarinic agents

Antimuscarinic agent	Preparation	Dosage (mg)	Frequency
Darifenacin	Controlled release	7.5-15	Once daily
Fesoterodine	Controlled release	4-8	Once daily
Oxybutynin	Immediate release	2.5-5	Two or three times a day Once daily
	Controlled release	5-20	
	Transdermal patch	36, releasing oxybutynin approximately 3.9 mg/24 hours	Replace once every 3-4 days

Propiverine	Immediate release	15	One to three times daily
	Controlled release	30	Once daily
Solifenacin	Controlled release	5-10	Once daily
Tolterodine	Immediate release	2-4	Once or twice daily
	Controlled release	4	Once daily
Trospium chloride	Immediate release	20	Twice daily (before food)
	Controlled release	60	Once daily

References

1. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. *Nat Rev Neurosci*. 2008;9(6):453-466.
2. Fowler CJ. Integrated control of lower urinary tract--clinical perspective. *Br J Pharmacol*. 2006;147 Suppl 2:S14-24.
3. Griffiths DJ. The Pontine Micturition Centres. *Scand J Urol Nephro*. 2002;Suppl 210:21-26.
4. Michels L, Blok BF, Gregorini F, et al. Supraspinal Control of Urine Storage and Micturition in Men--An fMRI Study. *Cereb Cortex*. 2014.
5. Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. *Lancet Neurol*. 2015;14(7):720-732.
6. de Groat WC. A neurologic basis for the overactive bladder. *Urology*. 1997;50(6A Suppl):36-52; discussion 53-36.
7. Panicker JN, Seth JH. C-fibre sensory nerves - not so silent as we think? *BJU Int*. 2013;112(1):129-130.
8. de Groat WC, Kawatani M, Hisamitsu T, et al. Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. *J Auton Nerv Syst*. 1990;30 Suppl:S71-77.
9. Martinez-Martin P, Schapira AH, Stocchi F, et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. *Mov Disord*. 2007;22(11):1623-1629.
10. Balash Y, Peretz C, Leibovich G, Herman T, Hausdorff JM, Giladi N. Falls in outpatients with Parkinson's disease: frequency, impact and identifying factors. *J Neurol*. 2005;252(11):1310-1315.
11. McGrother CW, Jagger C, Clarke M, Castleden CM. Handicaps associated with incontinence: implications for management. *Journal of epidemiology and community health*. 1990;44(3):246-248.
12. Smith M, Seth J, Batla A, Hofereiter J, Bhatia KP, Panicker JN. Nocturia in Patients With Parkinson's Disease. *Movement Disorders Clinical Practice*. 2016;3(2):168-172.
13. Sakakibara R, Panicker J, Finazzi-Agro E, Iacovelli V, Bruschini H, Parkinson's Disease Subcommittee TNPCiTICS. A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders. *Neurourol Urodyn*. 2015.
14. Sakakibara R, Panicker J, Simeoni S, et al. Bladder dysfunction as the initial presentation of multiple system atrophy: a prospective cohort study. *Clin Auton Res*. 2018.
15. Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Genitourinary dysfunction in Parkinson's disease. *Mov Disord*. 2010;25(1):2-12.
16. Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. *J Neurol Neurosurg Psychiatry*. 2001;71(5):600-606.
17. Sakakibara R, Kanda T, Sekido T, et al. Mechanism of bladder dysfunction in idiopathic normal pressure hydrocephalus. *Neurourol Urodyn*. 2008;27(6):507-510.
18. Ransmayr GN, Holliger S, Schletterer K, et al. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. *Neurology*. 2008;70(4):299-303.
19. Sink KM, Thomas J, 3rd, Xu H, Craig B, Kritchevsky S, Sands LP. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. *J Am Geriatr Soc*. 2008;56(5):847-853.
20. Han KS, Heo SH, Lee SJ, Jeon SH, Yoo KH. Comparison of urodynamics between ischemic and hemorrhagic stroke patients; can we suggest the category of urinary dysfunction in patients with cerebrovascular accident according to type of stroke? *Neurourol Urodyn*. 2010;29(3):387-390.
21. Kuchel GA, Moscufo N, Guttmann CR, et al. Localization of brain white matter hyperintensities and urinary incontinence in community-dwelling older adults. *J Gerontol A Biol Sci Med Sci*. 2009;64(8):902-909.
22. Tadic SD, Griffiths D, Murrin A, Schaefer W, Aizenstein HJ, Resnick NM. Brain activity during bladder filling is related to white matter structural changes in older women with urinary incontinence. *Neuroimage*. 2010;51(4):1294-1302.
23. Sakakibara R, Hattori T, Yasuda K, Yamanishi T. Micturitional disturbance after acute hemispheric stroke: analysis of the lesion site by CT and MRI. *J Neurol Sci*. 1996;137(1):47-56.
24. de Seze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B, Genulf. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. *Mult Scler*. 2007;13(7):915-928.
25. Mahajan ST, Patel PB, Marrie RA. Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry. *J Urol*. 2010;183(4):1432-1437.

26. Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis? *QJM*. 2004;97(10):671-676.
27. Phe V, Chartier-Kastler E, Panicker JN. Management of neurogenic bladder in patients with multiple sclerosis. *Nat Rev Urol*. 2016;13(5):275-288.
28. Blok B, Pannek J, Castro-Diaz D, et al. Guidelines on Neuro-Urology. European Association of Urology; 2015.
29. Podnar S, Fowler C. Pelvic organ dysfunction following cauda equina damage In: Fowler C, Panicker J, Emmanuel A, eds. *Pelvic Organ Dysfunction in Neurological Disease. Clinical Management and Rehabilitation*. Cambridge: Cambridge University Press; 2010.
30. Smith MD, Seth JH, Fowler CJ, Miller RF, Panicker JN. Urinary retention for the neurologist. *Pract Neurol*. 2013.
31. Panicker JN, Game X, Khan S, et al. The possible role of opiates in women with chronic urinary retention: observations from a prospective clinical study. *J Urol*. 2012;188(2):480-484.
32. Datta SN, Chaliha C, Singh A, et al. Sacral neurostimulation for urinary retention: 10-year experience from one UK centre. *BJU Int*. 2008;101(2):192-196.
33. Panicker JN, Seth JH, Khan S, et al. Open-label study evaluating outpatient urethral sphincter injections of onabotulinumtoxinA to treat women with urinary retention due to a primary disorder of sphincter relaxation (Fowler's syndrome). *BJU Int*. 2015.
34. Lawrenson R, Wyndaele JJ, Vlachonikolis I, Farmer C, Glickman S. Renal failure in patients with neurogenic lower urinary tract dysfunction. *Neuroepidemiology*. 2001;20(2):138-143.
35. Castel-Lacanal E, Game X, Clanet M, et al. Urinary complications and risk factors in symptomatic multiple sclerosis patients. Study of a cohort of 328 patients. *Neurourol Urodyn*. 2015;34(1):32-36.
36. Fourtassi M, Jacquin-Courtois S, Scheiber-Nogueira MC, et al. Bladder dysfunction in hereditary spastic paraplegia: a clinical and urodynamic evaluation. *Spinal Cord*. 2012;50(7):558-562.
37. Kessler TM. Diagnosis of urinary incontinence. *JAMA*. 2008;300(3):283; author reply 283.
38. NICE. Urinary incontinence in neurological disease (CG148). 2012.
39. Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2009;80(5):470-477.
40. Podnar S, Trsinar B, Vodusek DB. Bladder dysfunction in patients with cauda equina lesions. *Neurourol Urodyn*. 2006;25(1):23-31.
41. Palace J, Chandiramani VA, Fowler CJ. Value of sphincter EMG in the diagnosis of Multiple System Atrophy. *Muscle and Nerve*. 1997; **20**:1396-1403.
42. Panicker J, DasGupta R, Elneil S, Fowler C. Urinary Retention. In: Fowler C, Panicker J, Emmanuel A, eds. *Pelvic Organ Dysfunction in Neurological Disease. Clinical Management and Rehabilitation*. Cambridge: Cambridge University Press; 2010.
43. Gajewski JB, Awad SA. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. *J Urol*. 1986;135(5):966-968.
44. Stohrer M, Murtz G, Kramer G, Schnabel F, Arnold EP, Wyndaele JJ. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study. *Eur Urol*. 2007;51(1):235-242.
45. Mazo EB, Babanina GA. [Trospium chloride (spasmex) in the treatment of lower urinary tract symptoms in patients with neurogenic hyperactive urinary bladder caused by vertebrogenic lesions]. *Urologiia*. 2007(3):15-19.
46. Ethans KD, Nance PW, Bard RJ, Casey AR, Schryvers OI. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. *J Spinal Cord Med*. 2004;27(3):214-218.
47. van Rey F, Heesakkers J. Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. *Adv Urol*. 2011;2011:834753.
48. Madhuvrata P, Singh M, Hasafa Z, Abdel-Fattah M. Anticholinergic Drugs for Adult Neurogenic Detrusor Overactivity: A Systematic Review and Meta-analysis. *Eur Urol*. 2012.
49. Buser N, Ivic S, Kessler TM, Kessels AG, Bachmann LM. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. *Eur Urol*. 2012;62(6):1040-1060.
50. Gray SL, Anderson ML, Dublin S, et al. Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study. *JAMA Intern Med*. 2015.
51. Risacher SL, McDonald BC, Tallman EF, et al. Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. *JAMA Neurol*. 2016;73(6):721-732.
52. Fox C, Smith T, Maidment I, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. *Age Ageing*. 2014;43(5):604-615.

53. Davis TP, Sanchez-Covarubias L, Tome ME. P-glycoprotein trafficking as a therapeutic target to optimize CNS drug delivery. *Adv Pharmacol.* 2014;71:25-44.
54. Chancellor MB, Staskin DR, Kay GG, Sandage BW, Oefelein MG, Tsao JW. Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. *Drugs Aging.* 2012;29(4):259-273.
55. Wagg A, Verdejo C, Molander U. Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder. *Int J Clin Pract.* 2010;64(9):1279-1286.
56. Isik AT, Celik T, Bozoglu E, Doruk H. Trospium and cognition in patients with late onset Alzheimer disease. *J Nutr Health Aging.* 2009;13(8):672-676.
57. Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. *Neurourol Urodyn.* 2014;33(1):17-30.
58. Welk B, Hickling D, McKibbin M, Radomski S, Ethans K. A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction. *Neurourol Urodyn.* 2018;37(8):2810-2817.
59. Krhut J, Borovicka V, Bilkova K, et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study. *Neurourol Urodyn.* 2018;37(7):2226-2233.
60. Bosma R, Wynia K, Havlikova E, De Keyser J, Middel B. Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. *Acta Neurol Scand.* 2005;112(1):1-5.
61. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. *J Urol.* 2000;164(3 Pt 1):692-697.
62. Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. *N Engl J Med.* 2000;342(9):665.
63. Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. *European urology.* 2011;60(4):742-750.
64. Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. *J Urol.* 2012;187(6):2131-2139.
65. Giannantoni A, Mearini E, Del Zingaro M, Porena M. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. *European urology.* 2009;55(3):705-711.
66. Kennelly M, Dmochowski R, Ethans K, et al. Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis. *Urology.* 2013;81(3):491-497.
67. Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUMiT trial. *J Urol.* 2010;183(4):1438-1443.
68. Kabay SC, Kabay S, Yucel M, Ozden H. Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson's disease. *Neurourol Urodyn.* 2009;28(1):62-67.
69. Kabay S, Kabay SC, Yucel M, et al. The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. *Neurourol Urodyn.* 2009;28(8):964-968.
70. Gobbi C, Digesu GA, Khullar V, El Neil S, Caccia G, Zecca C. Percutaneous posterior tibial nerve stimulation as an effective treatment of refractory lower urinary tract symptoms in patients with multiple sclerosis: preliminary data from a multicentre, prospective, open label trial. *Mult Scler.* 2011;17(12):1514-1519.
71. Salatzki J, Liechti MD, Spanudakis E, et al. Factors influencing return for maintenance treatment with percutaneous tibial nerve stimulation for the management of the overactive bladder. *BJU Int.* 2018.
72. de Seze M, Raibaut P, Gallien P, et al. Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. *Neurourol Urodyn.* 2011;30(3):306-311.
73. Monteiro ES, de Carvalho LB, Fukujima MM, Lora MI, do Prado GF. Electrical stimulation of the posterior tibialis nerve improves symptoms of poststroke neurogenic overactive bladder in men: a randomized controlled trial. *Urology.* 2014;84(3):509-514.
74. Phe V, Pakzad M, Curtis C, et al. Urinary tract infections in multiple sclerosis. *Mult Scler.* 2016.
75. Seth JH, Haslam C, Panicker JN. Ensuring patient adherence to clean intermittent self-catheterization. *Patient Prefer Adherence.* 2014;8:191-198.

76. Prasad RS, Smith SJ, Wright H. Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. *Clin Rehabil.* 2003;17(1):42-47.
77. Naumann M, So Y, Argoff CE, et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology.* 2008;70(19):1707-1714.
78. Phe V, Pakzad M, Haslam C, et al. Open label feasibility study evaluating D-mannose combined with home-based monitoring of suspected urinary tract infections in patients with multiple sclerosis. *Neurourol Urodyn.* 2017;36(7):1770-1775.
79. Gallien P, Amarenco G, Benoit N, et al. Cranberry versus placebo in the prevention of urinary infections in multiple sclerosis: a multicenter, randomized, placebo-controlled, double-blind trial. *Mult Scler.* 2014;20(9):1252-1259.